Cost-effectiveness analysis of adding omega-3 or vitamin D supplementation to standard therapy in treating painful crises of pediatric sickle cell disease patients
Author
Abdelhalima, S.M.Murphy, J.E.
Meabed, M.H.
Elberry, A.A.
Gamaleldin, M.M.
Alshaeri, H.K.
Mohammad, B.A.
Hussein, R.R.S.
Affiliation
R. Ken Coit College of Pharmacy, University of ArizonaIssue Date
2022Keywords
ChildrenCost-effectiveness
Incremental costs
Incremental effects
Pediatrics
Sickle cell anemia
Sickle cell disease
Vaso-occlusion
Metadata
Show full item recordPublisher
Verduci Editore s.r.lCitation
Abdelhalima, S. M., Murphy, J. E., Meabed, M. H., Elberry, A. A., Gamaleldin, M. M., Alshaeri, H. K., Mohammad, B. A., & Hussein, R. R. S. (2022). Cost-effectiveness analysis of adding omega-3 or vitamin D supplementation to standard therapy in treating painful crises of pediatric sickle cell disease patients. European Review for Medical and Pharmacological Sciences, 26(20), 7506–7513.Rights
Copyright is held by the author(s) or the publisher. If your intended use exceeds the permitted uses specified by the license, contact the publisher for more information. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
OBJECTIVE: Painful crises represents a predominant complication of sickle cell disease (SCD). The only approved treatments for painful crises in many countries are hydroxyurea plus potent analgesics. Our earlier clinical trial concluded that omega-3 and vitamin D had a potential therapeutic impact on painful crises. However, there is limited research evaluating their therapeutic applications and cost-effectiveness. This paper aims at comparing the cost-effectiveness of omega-3 and vitamin D supplementation to the standard therapy in treating painful crises among children with SCD. PATIENTS AND METHODS: Cost-effectiveness analyses of daily supplementation of omega-3 and vitamin D were performed. The economic evaluation was based on data derived from a prospective 10-month randomized clinical trial (n = 165 patients; 15 patients dropped). 50 patients were recruited into the omega-3 + standard therapy group (hydroxyurea and folic acid daily with ibuprofen as needed), 50 patients into the vitamin D + standard therapy group, and 50 patients receiving standard therapy alone served as a control group. Outcome measures from the randomized clinical trial were used to determine incremental effectiveness. Cost estimates were calculated from the healthcare payer's perspective. The analysis considered the improvement in various outcome measures and are presented here as percent change from baseline to determine the incremental effectiveness and the incremental cost for the treatment of both interventions. RESULTS: Adding omega-3 or vitamin D to the standard therapy was more cost-effective than standard treatment alone. Vitamin D was a cheaper but less cost-effective alternative for most outcomes between the two treatments, including LDL-C and HDL-C. It was also more cost-effective but less clinically effective in reducing vaso-occlusive crisis episodes and pain severity. Omega-3 supplementation was significantly more cost-effective than vitamin D supplementation and the standard treatment for those measures. CONCLUSIONS: The present study showed that using vitamin D and omega-3 as add-on treatments for a painful crisis in pediatric sickle cell disease could have overall cost-saving and clinical benefits. However, further studies with a longer treatment duration are needed to establish more significant effects of the interventions for better policy and clinical decision-making. © 2022 Verduci Editore s.r.l. All rights reserved.Note
Open access journalISSN
1128-3602PubMed ID
36314321Version
Final published versionae974a485f413a2113503eed53cd6c53
10.26355/eurrev_202210_30021
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright is held by the author(s) or the publisher. If your intended use exceeds the permitted uses specified by the license, contact the publisher for more information. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Related articles
- Comparative effectiveness of adding Omega-3 or Vitamin D to standard therapy in preventing and treating episodes of painful crisis in pediatric sickle cell patients.
- Authors: Abdelhalim SM, Murphy JE, Meabed MH, Elberry AA, Gamaleldin MM, Shaalan MS, Hussein RRS
- Issue date: 2022 Jul
- Cost-effectiveness analysis of Manuka honey-Omega-3 combination treatments in treating oxidative stress of pediatric β-thalassemia major.
- Authors: Gamaleldin M, Abraham I, Meabed M, Elberry A, Abdelhalim S, Hussein A, Waggas D, Hussein R
- Issue date: 2024 Feb
- Magnesium for treating sickle cell disease.
- Authors: Than NN, Soe HHK, Palaniappan SK, Abas AB, De Franceschi L
- Issue date: 2017 Apr 14
- Magnesium for treating sickle cell disease.
- Authors: Than NN, Soe HHK, Palaniappan SK, Abas AB, De Franceschi L
- Issue date: 2019 Sep 9
- Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
- Authors: Adel AM, Abushanab D, Al-Badriyeh D, Hamad A, Alshurafa A, Yassin MA
- Issue date: 2024